Literature DB >> 8738759

Stereoselective pharmacokinetics of methadone in chronic pain patients.

K Kristensen1, T Blemmer, H R Angelo, L L Christrup, N E Drenck, S N Rasmussen, P Sjøgren.   

Abstract

Ten patients with chronic pain were randomized to an open, balanced, crossover study. Each patients received two different preparations of racemic methadone, i.e., tablets and intravenous infusion. The pharmacokinetic parameters of the R- and S-enantiomers of the racemate are reported. The analgesically active R-methadone has a significantly longer mean elimination half-life than the optical antipode S-methadone (t1/2 = 37.5 and 28.6 h, respectively). The mean total volume of distribution is 496.6 L for R-methadone and 289.1 L for S-methadone. Significant differences in the mean clearance between R- and S-methadone are seen (0.158 and 0.129 L/min, respectively). However, the lagtime after oral administration and the bioavailability did not show differences between the isomers. The data suggest that both enantiomers of methadone should be measured if correlations between pharmacodynamics and kinetics are made due to the stereoselective differences in half-life, total volume of distribution, and clearance.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8738759     DOI: 10.1097/00007691-199606000-00001

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  27 in total

1.  Population pharmacokinetics of methadone in opiate users: characterization of time-dependent changes.

Authors:  A Rostami-Hodjegan; K Wolff; A W Hay; D Raistrick; R Calvert; G T Tucker
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Toxicology and pathology of deaths related to methadone: retrospective review.

Authors:  S B Karch; B G Stephens
Journal:  West J Med       Date:  2000-01

3.  Population pharmacokinetics of (R)-, (S)- and rac-methadone in methadone maintenance patients.

Authors:  David J R Foster; Andrew A Somogyi; Jason M White; Felix Bochner
Journal:  Br J Clin Pharmacol       Date:  2004-06       Impact factor: 4.335

4.  Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliation.

Authors:  Yan Chang; Wenfang B Fang; Shen-Nan Lin; David E Moody
Journal:  Basic Clin Pharmacol Toxicol       Date:  2010-09-02       Impact factor: 4.080

5.  Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model.

Authors:  Feng Yang; Xianping Tong; D Gail McCarver; Ronald N Hines; Daniel A Beard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-06-07       Impact factor: 2.745

6.  Methadone dosing strategies in preterm neonates can be simplified.

Authors:  Tamara van Donge; Samira Samiee-Zafarghandy; Marc Pfister; Gilbert Koch; Majid Kalani; Arash Bordbar; John van den Anker
Journal:  Br J Clin Pharmacol       Date:  2019-04-10       Impact factor: 4.335

Review 7.  Interindividual variability of the clinical pharmacokinetics of methadone: implications for the treatment of opioid dependence.

Authors:  Chin B Eap; Thierry Buclin; Pierre Baumann
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

8.  Functional genetic polymorphisms in CYP2C19 gene in relation to cardiac side effects and treatment dose in a methadone maintenance cohort.

Authors:  Sheng-Chang Wang; Ing-Kang Ho; Hsiao-Hui Tsou; Sheng-Wen Liu; Chin-Fu Hsiao; Chia-Hui Chen; Happy Kuy-Lok Tan; Linen Lin; Chi-Shin Wu; Lien-Wen Su; Chieh-Liang Huang; Yi-Hong Yang; Ming-Lun Liu; Keh-Ming Lin; Shu Chih Liu; Hsiao-Yu Wu; Hsiang-Wei Kuo; Andrew C H Chen; Yao-Sheng Chang; Yu-Li Liu
Journal:  OMICS       Date:  2013-09-09

9.  Bioavailabilities of rectal and oral methadone in healthy subjects.

Authors:  Ola Dale; Pamela Sheffels; Evan D Kharasch
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.